U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06974929) titled 'A Clinical Study of HRS-6209 in Combination With Letrozole in Patients With Breast Cancer' on May 08.
Brief Summary: This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with letrozole in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: HRS-6209 Capsules
Oral HRS-6209 capsules.
DRUG: Letrozole Tablets
Oral Letrozole tablets.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Published by HT Digital Content Ser...